Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn/winter campaign in the EU/EEA, according to a new report from the European Centre for Disease Prevention and Control (ECDC).

During the COVID-19 pandemic, levels of seasonal influenza virus circulation were unprecedentedly low, leading to concerns that a lack of exposure to influenza viruses, combined with waning antibody titres.

In an epidemiological update, the ECDC urges EU/EEA Member States to strengthen vaccination campaigns and prepare for the possible need to increase emergency department and ICU capacity

Previous comparative analyses of people admitted to hospital for COVID-19 versus influenza evaluated the risk of death, hospital readmission, and a narrow set of health outcomes up to 6 months following infection.

Since 2018, the work of the European Commission on vaccination has been guided by the Council Recommendation on strengthened cooperation against vaccine-preventable diseases. The aim of this report is to support possible policy developments in the future.

Chaired by DG SANTE, EU Member States agreed on prioritising for 2024-2026: health promotion & prevention of non-communicable diseases; healthy longevity/lifelong prevention; vaccine-preventable diseases & vaccination; and long COVID, amongst others.

This webinar provides an overview of WHO resources available to support countries in developing/strengthening their programmes and highlight examples of national and regional good practices for seasonal influenza prevention and control.

On the first-ever Health Day at a COP, more than 40 million health professionals from around the globe joined the call to action by the WHO and civil society organizations, to prioritize health in climate negotiations at COP28.

ESWI endorses a joint statement initiated by ERS and ELF to prioritise action to mitigate but also adapt to the health effects of climate change, to prepare societies and communities for a much more complex future.

ESWI 2023: 10 key take home messages

Oral Antiviral (OAV) COVID-19 treatments are widely used, but evidence for their effectiveness against the Omicron variant in higher risk, vaccinated individuals is limited.